Transduction of Human CD34 + Repopulating Cells with a Self-Inactivating Lentiviral Vector for SCID-X1 Produced at Clinical Scale by a Stable Cell Line
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Self-inactivating (SIN)-lentiviral vectors have safety and efficacy features that are well suited for transduction of hematopoietic stem cells (HSCs), but generation of vector at clinical scale has been challenging. Approximately 280 liters of an X-Linked Severe Combined Immunodeficiency Disorder (SCID-X1) SIN-lentiviral vector in two productions from a stable cell line were concentrated to final titers of 4.5 and 7.2×108 tu/ml. These two clinical preparations and three additional development-scale preparations were evaluated in human CD34+ hematopoietic cells in vitro using colony forming cell (CFU-C) assay and in vivo using the NOD/Lt-scid/IL2Rγnull (NSG) mouse xenotransplant model. A 40-hour transduction protocol using a single vector exposure conferred a mean NSG repopulating cell transduction of 0.23 vector genomes/human genome with a mean myeloid vector copy number of 3.2 vector genomes/human genome. No adverse effects on engraftment were observed from vector treatment. Direct comparison between our SIN-lentiviral vector using a 40-hour protocol and an MFGγc γ-retroviral vector using a five-day protocol demonstrated equivalent NSG repopulating cell transduction efficiency. Clonality survey by linear amplification-mediated polymerase chain reaction (LAM-PCR) with Illumina sequencing revealed common clones in sorted myeloid and lymphoid populations from engrafted mice demonstrating multipotent cell transduction. These vector preparations will be used in two clinical trials for SCID-X1. Greene and colleagues report that they have successfully produced a self-inactivating (SIN) lentiviral vector at a large enough scale for two clinical trials for SCID-X1. They demonstrate that this vector has reproducible transduction efficiency both in vitro and in vivo and that no adverse effects on engraftment were observed in NOD/Lt-scid/IL2Rγnull (NSG) mice.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1
Hacein-Bey-Abina, S., Garrigue, A., Wang, G. P., Soulier, J., Lim, A., Morillon, E., Clappier, E., Caccavelli, L., Delabesse, E., Beldjord, K., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci35700 · Cited by 1,854 · cited 2×
“Insertional oncogenesis due to proto-oncogene activation has been observed using murine c-retroviral vectors in clinical trials, at first only in severe combined immunodeficiency disorder (SCID-X1) SIN-lentiviral vector (Hacein-Bey-Abina et al., 2003; Hacein-Bey-Abina et al., 2008; Howe et al., 2008) but later in othe…”
BackgroundMethodHIV-1 Integration in the Human Genome Favors Active Genes and Local Hotspots
Schröder, A. R. W., Shinn, P., Chen, H., Berry, C., Ecker, J. R., & Bushman, F. (2002) · Cell · doi:10.1016/s0092-8674(02)00864-4 · Cited by 1,832
Self-Inactivating Lentivirus Vector for Safe and Efficient In Vivo Gene Delivery
Zufferey, R., Dull, T., Mandel, R. J., Bukovsky, A., Quiroz, D., Naldini, L., & Trono, D. (1998) · Journal of Virology · doi:10.1128/jvi.72.12.9873-9880.1998 · Cited by 1,815
Hematopoietic Stem Cell Gene Therapy with a Lentiviral Vector in X-Linked Adrenoleukodystrophy
Cartier, N., Hacein-Bey-Abina, S., Bartholomae, C. C., Veres, G., Schmidt, M., Kutschera, I., Vidaud, M., Abel, U., Dal-Cortivo, L., Caccavelli, L., et al. (2009) · Science · doi:10.1126/science.1171242 · Cited by 1,508 · cited 6×
“Our transduction results also compare favorably with published lentiviral trials targeting CD34 + cells for X-linked adrenoleukodystrophy (ALD)(Cartier et al., 2009; Cartier et al., 2012), b-Thalassemia (Cavazzana-Calvo et al., 2010), and Wiskott-Aldrich Syndrome (WAS) (Merten et al., 2011; Scaramuzza et al., 2012).”
MethodResultInfluentialTranscription Start Regions in the Human Genome Are Favored Targets for MLV Integration
Wu, X., Li, Y., Crise, B., & Burgess, S. M. (2003) · Science · doi:10.1126/science.1083413 · Cited by 1,305 · cited 2×
“…vectors may be intrinsically safer than c-retroviral vectors (Montini et al., 2006) because of a different insertional profile, which less frequently targets gene regulatory regions and specific proto-oncogenes (Schröder et al., 2002; Wu et al., 2003; Hematti et al., 2004; Mitchell et al., 2004).”
BackgroundTransfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia
Cavazzana-Calvo, M., Payen, E., Negre, O., Wang, G., Hehir, K., Fusil, F., Down, J., Denaro, M., Brady, T., Westerman, K., et al. (2010) · Nature · doi:10.1038/nature09328 · Cited by 1,276 · cited 3×
“Lentiviral vectors can potentially cause clonal imbalance in human subjects (Cavazzana-Calvo et al., 2010) and leukemia in animal models (Montini et al., 2009), suggesting the need to limit the vector copy number.”
BackgroundResultMontini, E., Cesana, D., Schmidt, M., Sanvito, F., Bartholomae, C. C., Ranzani, M., Benedicenti, F., Sergi, L. S., Ambrosi, A., Ponzoni, M., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci37630 · Cited by 571 · cited 4×
“, 1998) coupled to the use of an internal cellular promoter, (Zychlinski et al., 2008; Montini et al., 2009) and the incorporation of insulator elements to block transcriptional activation of neighboring genes originating from within the vector (Evans-Galea et al.”
BackgroundInfluentialHigh-resolution insertion-site analysis by linear amplification-mediated PCR (LAM-PCR)
Schmidt, M., Schwarzwaelder, K., Bartholomae, C., Zaoui, K., Ball, C., Pilz, I., Braun, S., Glimm, H., & von Kalle, C. (2007) · Nature Methods · doi:10.1038/nmeth1103 · Cited by 328 · cited 5×
“The authors would like to thank Adrian Thrasher (Great Ormond Street Hospital NHS Trust, London, UK) for the generous gifts of the ED7R cell line and the MFGcc producer cell line, Susan Sleep (Children’s GMP, LLC, Memphis, TN) for the ED7R titrations and quality control analysis of the clinical preparations, Harry Mal…”
MethodInfluentialPhysiological Promoters Reduce the Genotoxic Risk of Integrating Gene Vectors
Zychlinski, D., Schambach, A., Modlich, U., Maetzig, T., Meyer, J., Grassman, E., Mishra, A., & Baum, C. (2008) · Molecular Therapy · doi:10.1038/mt.2008.5 · Cited by 271
Zhou, S., Mody, D., DeRavin, S. S., Hauer, J., Lu, T., Ma, Z., Hacein-Bey Abina, S., Gray, J. T., Greene, M. R., Cavazzana-Calvo, M., et al. (2010) · Blood · doi:10.1182/blood-2009-10-250209 · Cited by 119 · cited 3×
“…create CL204i-EF1a-hcc-OPT, a SIN-lentiviral vector for the treatment of SCID-X1 that incorporates an internal EF1a promoter to drive expression of a human IL-2Rcc codon-optimized cDNA and flanked by the 400 bp version of the chicken b-Globin HS4 insulator (Throm et al., 2009; Zhou et al., 2010).”
BackgroundMethodSelf-citation
Cited by
Production of lentiviral vectors
Merten, O.-W., Hebben, M., & Bovolenta, C. (2016) · Molecular Therapy - Methods & Clinical Development · doi:10.1038/mtm.2016.17 · Cited by 294
Progress and challenges in viral vector manufacturing
van der Loo, J. C. M., & Wright, J. F. (2016) · Human Molecular Genetics · doi:10.1093/hmg/ddv451 · Cited by 255
Lentiviral hematopoietic stem cell gene therapy for X-linked severe combined immunodeficiency
De Ravin, S. S., Wu, X., Moir, S., Kardava, L., Anaya-O’Brien, S., Kwatemaa, N., Littel, P., Theobald, N., Choi, U., Su, L., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aad8856 · Cited by 244
Self-citationCurrent challenges in biotherapeutic particles manufacturing
Moleirinho, M. G., Silva, R. J. S., Alves, P. M., Carrondo, M. J. T., & Peixoto, C. (2020) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2020.1693541 · Cited by 123
Construction of stable packaging cell lines for clinical lentiviral vector production
Sanber, K. S., Knight, S. B., Stephen, S. L., Bailey, R., Escors, D., Minshull, J., Santilli, G., Thrasher, A. J., Collins, M. K., & Takeuchi, Y. (2015) · Scientific Reports · doi:10.1038/srep09021 · Cited by 108
Metadata
- Authors
- Greene, M. R., Lockey, T., Mehta, P. K., Kim, Y.-S., Eldridge, P. W., Gray, J. T., & Sorrentino, B. P.
- Venue
- Human Gene Therapy Methods
- Publisher
- SAGE Publications
- Published
- 2012-10
- Volume
- 23
- Issue
- 5
- Pages
- 297-308
- ISSN
- 1946-6536 (ISSN-L)
- 1946-6544
- OpenAlex
- W2027678303
- Cited by
- 47
- References
- 10
- FWCI
- 1.77
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.